238 related articles for article (PubMed ID: 37957317)
1. The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation.
Nelson MR; Liu P; Agrawal A; Yip O; Blumenfeld J; Traglia M; Kim MJ; Koutsodendris N; Rao A; Grone B; Hao Y; Yoon SY; Xu Q; De Leon S; Choenyi T; Thomas R; Lopera F; Quiroz YT; Arboleda-Velasquez JF; Reiman EM; Mahley RW; Huang Y
Nat Neurosci; 2023 Dec; 26(12):2104-2121. PubMed ID: 37957317
[TBL] [Abstract][Full Text] [Related]
2. Humanized APOE genotypes influence lifespan independently of tau aggregation in the P301S mouse model of tauopathy.
Williams T; Bathe T; Vo Q; Sacilotto P; McFarland K; Ruiz AJ; Hery GP; Sullivan P; Borchelt DR; Prokop S; Chakrabarty P
Acta Neuropathol Commun; 2023 Jun; 11(1):99. PubMed ID: 37337279
[TBL] [Abstract][Full Text] [Related]
3. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy.
Shi Y; Yamada K; Liddelow SA; Smith ST; Zhao L; Luo W; Tsai RM; Spina S; Grinberg LT; Rojas JC; Gallardo G; Wang K; Roh J; Robinson G; Finn MB; Jiang H; Sullivan PM; Baufeld C; Wood MW; Sutphen C; McCue L; Xiong C; Del-Aguila JL; Morris JC; Cruchaga C; ; Fagan AM; Miller BL; Boxer AL; Seeley WW; Butovsky O; Barres BA; Paul SM; Holtzman DM
Nature; 2017 Sep; 549(7673):523-527. PubMed ID: 28959956
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist.
Litvinchuk A; Suh JH; Guo JL; Lin K; Davis SS; Bien-Ly N; Tycksen E; Tabor GT; Remolina Serrano J; Manis M; Bao X; Lee C; Bosch M; Perez EJ; Yuede CM; Cashikar AG; Ulrich JD; Di Paolo G; Holtzman DM
Neuron; 2024 Feb; 112(3):384-403.e8. PubMed ID: 37995685
[TBL] [Abstract][Full Text] [Related]
5. Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits.
Koutsodendris N; Blumenfeld J; Agrawal A; Traglia M; Grone B; Zilberter M; Yip O; Rao A; Nelson MR; Hao Y; Thomas R; Yoon SY; Arriola P; Huang Y
Nat Aging; 2023 Mar; 3(3):275-296. PubMed ID: 37118426
[TBL] [Abstract][Full Text] [Related]
6.
Naguib S; Torres ER; Lopez-Lee C; Fan L; Bhagwat M; Norman K; Lee SI; Zhu J; Ye P; Wong MY; Patel T; Mok SA; Luo W; Sinha S; Zhao M; Gong S; Gan L
bioRxiv; 2024 Apr; ():. PubMed ID: 38712164
[TBL] [Abstract][Full Text] [Related]
7. Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk.
Huang YA; Zhou B; Nabet AM; Wernig M; Südhof TC
J Neurosci; 2019 Sep; 39(37):7408-7427. PubMed ID: 31331998
[TBL] [Abstract][Full Text] [Related]
8. Impact of APOE genotype on prion-type propagation of tauopathy.
Williams T; Ruiz AJ; Ruiz AM; Vo Q; Tsering W; Xu G; McFarland K; Giasson BI; Sullivan P; Borchelt DR; Chakrabarty P
Acta Neuropathol Commun; 2022 Apr; 10(1):57. PubMed ID: 35440098
[TBL] [Abstract][Full Text] [Related]
9. Interaction of ApoE3 and ApoE4 isoforms with an ITM2b/BRI2 mutation linked to the Alzheimer disease-like Danish dementia: Effects on learning and memory.
Biundo F; Ishiwari K; Del Prete D; D'Adamio L
Neurobiol Learn Mem; 2015 Dec; 126():18-30. PubMed ID: 26528887
[TBL] [Abstract][Full Text] [Related]
10. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.
Brecht WJ; Harris FM; Chang S; Tesseur I; Yu GQ; Xu Q; Dee Fish J; Wyss-Coray T; Buttini M; Mucke L; Mahley RW; Huang Y
J Neurosci; 2004 Mar; 24(10):2527-34. PubMed ID: 15014128
[TBL] [Abstract][Full Text] [Related]
11. APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer's disease patient iPSC-derived cerebral organoids.
Zhao J; Fu Y; Yamazaki Y; Ren Y; Davis MD; Liu CC; Lu W; Wang X; Chen K; Cherukuri Y; Jia L; Martens YA; Job L; Shue F; Nguyen TT; Younkin SG; Graff-Radford NR; Wszolek ZK; Brafman DA; Asmann YW; Ertekin-Taner N; Kanekiyo T; Bu G
Nat Commun; 2020 Nov; 11(1):5540. PubMed ID: 33139712
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model.
Litvinchuk A; Huynh TV; Shi Y; Jackson RJ; Finn MB; Manis M; Francis CM; Tran AC; Sullivan PM; Ulrich JD; Hyman BT; Cole T; Holtzman DM
Ann Neurol; 2021 May; 89(5):952-966. PubMed ID: 33550655
[TBL] [Abstract][Full Text] [Related]
13. In Thai Nationals, the ApoE4 Allele Affects Multiple Domains of Neuropsychological, Biobehavioral, and Social Functioning Thereby Contributing to Alzheimer's Disorder, while the ApoE3 Allele Protects Against Neuropsychiatric Symptoms and Psychosocial Deficits.
Tangwongchai S; Supasitthumrong T; Hemrunroj S; Tunvirachaisakul C; Chuchuen P; Houngngam N; Snabboon T; Tawankanjanachot I; Likitchareon Y; Phanthumchindad K; Maes M
Mol Neurobiol; 2018 Aug; 55(8):6449-6462. PubMed ID: 29307083
[TBL] [Abstract][Full Text] [Related]
14. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia.
Wang C; Xiong M; Gratuze M; Bao X; Shi Y; Andhey PS; Manis M; Schroeder C; Yin Z; Madore C; Butovsky O; Artyomov M; Ulrich JD; Holtzman DM
Neuron; 2021 May; 109(10):1657-1674.e7. PubMed ID: 33831349
[TBL] [Abstract][Full Text] [Related]
15. Independent APOE4 knock-in mouse models display reduced brain APOE protein, altered neuroinflammation, and simplification of dendritic spines.
Sepulveda J; Luo N; Nelson M; Ng CAS; Rebeck GW
J Neurochem; 2022 Nov; 163(3):247-259. PubMed ID: 35838553
[TBL] [Abstract][Full Text] [Related]
16. Reversal of ApoE4-Driven Brain Pathology by Vascular Endothelial Growth Factor Treatment.
Salomon-Zimri S; Glat MJ; Barhum Y; Luz I; Boehm-Cagan A; Liraz O; Ben-Zur T; Offen D; Michaelson DM
J Alzheimers Dis; 2016 Jun; 53(4):1443-58. PubMed ID: 27372644
[TBL] [Abstract][Full Text] [Related]
17. APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.
Fernández-Calle R; Konings SC; Frontiñán-Rubio J; García-Revilla J; Camprubí-Ferrer L; Svensson M; Martinson I; Boza-Serrano A; Venero JL; Nielsen HM; Gouras GK; Deierborg T
Mol Neurodegener; 2022 Sep; 17(1):62. PubMed ID: 36153580
[TBL] [Abstract][Full Text] [Related]
18. Central and Peripheral Mechanisms in ApoE4-Driven Diabetic Pathology.
Koren-Iton A; Salomon-Zimri S; Smolar A; Shavit-Stein E; Dori A; Chapman J; Michaelson DM
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32075060
[TBL] [Abstract][Full Text] [Related]
19. APOE modulates the effect of estrogen therapy on Aβ accumulation EFAD-Tg mice.
Kunzler J; Youmans KL; Yu C; Ladu MJ; Tai LM
Neurosci Lett; 2014 Feb; 560():131-6. PubMed ID: 24368217
[TBL] [Abstract][Full Text] [Related]
20. Astrocyte-secreted glypican-4 drives APOE4-dependent tau hyperphosphorylation.
Saroja SR; Gorbachev K; Julia T; Goate AM; Pereira AC
Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2108870119. PubMed ID: 35969759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
